Global Markets Direct’s, ‘Hypertension – Pipeline Review, H2 2015′, provides an overview of the Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Hypertension
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Hypertension
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 8
Hypertension Overview 9
Therapeutics Development 10
Hypertension - Therapeutics under Development by Companies 12
Hypertension - Therapeutics under Investigation by Universities/Institutes 21
Hypertension - Pipeline Products Glance 23
Hypertension - Products under Development by Companies 27
Hypertension - Products under Investigation by Universities/Institutes 40
Hypertension - Companies Involved in Therapeutics Development 42
Hypertension - Therapeutics Assessment 144
Drug Profiles 174
Hypertension - Recent Pipeline Updates 418
Hypertension - Dormant Projects 484
Hypertension - Discontinued Products 505
Hypertension - Product Development Milestones 508
Appendix 517

List of Tables

Number of Products under Development for Hypertension, H2 2015 31
Number of Products under Development for Hypertension - Comparative Analysis, H2 2015 32
Number of Products under Development by Companies, H2 2015 34
Number of Products under Development by Companies, H2 2015 (Contd..1) 35
Number of Products under Development by Companies, H2 2015 (Contd..2) 36
Number of Products under Development by Companies, H2 2015 (Contd..3) 37
Number of Products under Development by Companies, H2 2015 (Contd..4) 38
Number of Products under Development by Companies, H2 2015 (Contd..5) 39
Number of Products under Development by Companies, H2 2015 (Contd..6) 40
Number of Products under Development by Companies, H2 2015 (Contd..7) 41
Number of Products under Investigation by Universities/Institutes, H2 2015 43
Comparative Analysis by Late Stage Development, H2 2015 44
Comparative Analysis by Clinical Stage Development, H2 2015 45
Comparative Analysis by Early Stage Development, H2 2015 46
Comparative Analysis by Unknown Stage Development, H2 2015 47
Products under Development by Companies, H2 2015 48
Products under Development by Companies, H2 2015 (Contd..1) 49
Products under Development by Companies, H2 2015 (Contd..2) 50
Products under Development by Companies, H2 2015 (Contd..3) 51
Products under Development by Companies, H2 2015 (Contd..4) 52
Products under Development by Companies, H2 2015 (Contd..5) 53
Products under Development by Companies, H2 2015 (Contd..6) 54
Products under Development by Companies, H2 2015 (Contd..7) 55
Products under Development by Companies, H2 2015 (Contd..8) 56
Products under Development by Companies, H2 2015 (Contd..9) 57
Products under Development by Companies, H2 2015 (Contd..10) 58
Products under Development by Companies, H2 2015 (Contd..11) 59
Products under Development by Companies, H2 2015 (Contd..12) 60
Products under Investigation by Universities/Institutes, H2 2015 61
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 62
Hypertension - Pipeline by A1M Pharma AB, H2 2015 63
Hypertension - Pipeline by AbbVie Inc., H2 2015 64
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 65
Hypertension - Pipeline by Actelion Ltd, H2 2015 66
Hypertension - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 67
Hypertension - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 68
Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 69
Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2015 70
Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2015 71
Hypertension - Pipeline by Ascendis Pharma A/S, H2 2015 72
Hypertension - Pipeline by Bayer AG, H2 2015 73
Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2015 74
Hypertension - Pipeline by Bio-inRen, H2 2015 75
Hypertension - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015 76
Hypertension - Pipeline by BioLineRx, Ltd., H2 2015 77
Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2015 78
Hypertension - Pipeline by Carolus Therapeutics, Inc., H2 2015 79
Hypertension - Pipeline by Cellceutix Corporation, H2 2015 80
Hypertension - Pipeline by Celsion Corporation, H2 2015 81
Hypertension - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2015 82
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 83
Hypertension - Pipeline by CJ HealthCare Corp., H2 2015 84
Hypertension - Pipeline by Complexa, Inc., H2 2015 85
Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2015 86
Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H2 2015 87
Hypertension - Pipeline by Cytokinetics, Inc., H2 2015 88
Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 89
Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 90
Hypertension - Pipeline by DiaMedica Inc., H2 2015 91
Hypertension - Pipeline by Dong-A Socio Group, H2 2015 92
Hypertension - Pipeline by Eli Lilly and Company, H2 2015 93
Hypertension - Pipeline by Esperion Therapeutics, Inc., H2 2015 94
Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2015 95
Hypertension - Pipeline by Gilead Sciences, Inc., H2 2015 96
Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2015 97
Hypertension - Pipeline by Glenveigh Medical, LLC, H2 2015 98
Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 99
Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 100
Hypertension - Pipeline by Innopharmax Inc., H2 2015 101
Hypertension - Pipeline by Insmed Incorporated, H2 2015 102
Hypertension - Pipeline by IntelGenx Corp., H2 2015 103
Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 104
Hypertension - Pipeline by Ionis Pharmaceuticals, Inc., H2 2015 105
Hypertension - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 106
Hypertension - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 107
Hypertension - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 108
Hypertension - Pipeline by JW Pharmaceutical Corporation, H2 2015 109
Hypertension - Pipeline by Kowa Company, Ltd., H2 2015 110
Hypertension - Pipeline by Lacer, S.A., H2 2015 111
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 112
Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2015 113
Hypertension - Pipeline by LG Life Science LTD., H2 2015 114
Hypertension - Pipeline by LinXis B.V., H2 2015 115
Hypertension - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2015 116
Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015 117
Hypertension - Pipeline by Merck & Co., Inc., H2 2015 118
Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2015 119
Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2015 120
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 121
Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2015 122
Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2015 123
Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 124
Hypertension - Pipeline by Novartis AG, H2 2015 125
Hypertension - Pipeline by Noxamet Ltd, H2 2015 126
Hypertension - Pipeline by Omeros Corporation, H2 2015 127
Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 128
Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2015 129
Hypertension - Pipeline by Pfizer Inc., H2 2015 130
Hypertension - Pipeline by PharmaIN Corporation, H2 2015 131
Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015 132
Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2015 133
Hypertension - Pipeline by Proteo, Inc. (Inactive), H2 2015 134
Hypertension - Pipeline by Pulmokine, Inc., H2 2015 135
Hypertension - Pipeline by Quantum Genomics SA, H2 2015 136
Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2015 137
Hypertension - Pipeline by RedHill Biopharma Ltd., H2 2015 138
Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2015 139
Hypertension - Pipeline by rEVO Biologics, Inc., H2 2015 140
Hypertension - Pipeline by Sanofi, H2 2015 141
Hypertension - Pipeline by Selten Pharma, Inc, H2 2015 142
Hypertension - Pipeline by Serodus ASA, H2 2015 143
Hypertension - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015 144
Hypertension - Pipeline by Silence Therapeutics Plc, H2 2015 145
Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2015 146
Hypertension - Pipeline by Sinoxa Pharma GmbH, H2 2015 147
Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2015 148
Hypertension - Pipeline by Suda Ltd, H2 2015 149
Hypertension - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 150
Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 151
Hypertension - Pipeline by Symplmed, Inc., H2 2015 152
Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 153
Hypertension - Pipeline by The Medicines Company, H2 2015 154
Hypertension - Pipeline by Theravance Biopharma, Inc., H2 2015 155
Hypertension - Pipeline by Toray Industries, Inc., H2 2015 156
Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H2 2015 157
Hypertension - Pipeline by TSH Biopharm Corporation Limited, H2 2015 158
Hypertension - Pipeline by vasopharm GmbH, H2 2015 159
Hypertension - Pipeline by VBS Pharmaceuticals, H2 2015 160
Hypertension - Pipeline by Vectura Group Plc, H2 2015 161
Hypertension - Pipeline by VG Life Sciences, Inc., H2 2015 162
Hypertension - Pipeline by Vicore Pharma AB, H2 2015 163
Hypertension - Pipeline by Yuhan Corporation, H2 2015 164
Assessment by Monotherapy Products, H2 2015 165
Assessment by Combination Products, H2 2015 166
Number of Products by Stage and Target, H2 2015 168
Number of Products by Stage and Mechanism of Action, H2 2015 186
Number of Products by Stage and Route of Administration, H2 2015 192
Number of Products by Stage and Molecule Type, H2 2015 194
Hypertension Therapeutics - Recent Pipeline Updates, H2 2015 439
Hypertension - Dormant Projects, H2 2015 505
Hypertension - Dormant Projects (Contd..1), H2 2015 506
Hypertension - Dormant Projects (Contd..2), H2 2015 507
Hypertension - Dormant Projects (Contd..3), H2 2015 508
Hypertension - Dormant Projects (Contd..4), H2 2015 509
Hypertension - Dormant Projects (Contd..5), H2 2015 510
Hypertension - Dormant Projects (Contd..6), H2 2015 511
Hypertension - Dormant Projects (Contd..7), H2 2015 512
Hypertension - Dormant Projects (Contd..8), H2 2015 513
Hypertension - Dormant Projects (Contd..9), H2 2015 514
Hypertension - Dormant Projects (Contd..10), H2 2015 515
Hypertension - Dormant Projects (Contd..11), H2 2015 516
Hypertension - Dormant Projects (Contd..12), H2 2015 517
Hypertension - Dormant Projects (Contd..13), H2 2015 518
Hypertension - Dormant Projects (Contd..14), H2 2015 519
Hypertension - Dormant Projects (Contd..15), H2 2015 520
Hypertension - Dormant Projects (Contd..16), H2 2015 521
Hypertension - Dormant Projects (Contd..17), H2 2015 522
Hypertension - Dormant Projects (Contd..18), H2 2015 523
Hypertension - Dormant Projects (Contd..19), H2 2015 524
Hypertension - Dormant Projects (Contd..20), H2 2015 525
Hypertension - Discontinued Products, H2 2015 526
Hypertension - Discontinued Products (Contd..1), H2 2015 527
Hypertension - Discontinued Products (Contd..2), H2 2015 528

List of Figures

Number of Products under Development for Hypertension, H2 2015 31
Number of Products under Development for Hypertension - Comparative Analysis, H2 2015 32
Number of Products under Development by Companies, H2 2015 33
Number of Products under Investigation by Universities/Institutes, H2 2015 42
Comparative Analysis by Late Stage Development, H2 2015 44
Comparative Analysis by Clinical Stage Development, H2 2015 45
Comparative Analysis by Early Stage Products, H2 2015 46
Assessment by Monotherapy Products, H2 2015 165
Assessment by Combination Products, H2 2015 166
Number of Products by Top 10 Targets, H2 2015 167
Number of Products by Stage and Top 10 Targets, H2 2015 167
Number of Products by Top 10 Mechanism of Actions, H2 2015 185
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 185
Number of Products by Top 10 Routes of Administration, H2 2015 191
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 191
Number of Products by Top 10 Molecule Types, H2 2015 193
Number of Products by Stage and Top 10 Molecule Types, H2 2015 193